| 價格 | ¥17500 | ¥13800 | ¥10600 |
| 包裝 | 100mg | 50mg | 25mg |
| 最小起訂量 | 25mg |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-05-08 |
| 中文名稱:化合物 Ro 04-5595 free base | 英文名稱:Ro 04-5595 free base |
| CAS:194089-07-1 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 產(chǎn)品類別: 抑制劑 | |
| 貨號: T70049 |
| 名稱 | Ro 04-5595 free base |
| 描述 | Ro 04-5595 is a selective antagonist of NMDA receptors NR2B subunits. Ro 04-5595 had an EC 50 of 186 ± 32 nmol/L. Ro 04-5595 was predicted to bind the EVT-101 binding site, not the ifenprodil-binding site. Specific binding, defined with a new NR2B-specific antagonist Ro 04-5595 at 10 microM was fully inhibited by several compounds with the following rank order of affinities--Ro 25-6981 > CP-101,606 > Ro 04-5595 = ifenprodil >> eliprodil > haloperidol > spermine > spermidine > MgCl2 > CaCl2--and partially inhibited by competitive glutamate recognition site antagonists. Complementary high-resolution autoradiographic images using [3H]Ro04-5595 demonstrated strong binding in NR2B receptor-rich regions and low binding in cerebellum where NR2B concentration is low. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 關(guān)鍵字 | Ro 04-5595 free base | Ro 04-5595 | CHC-2014 | CHC2014 | CHC 2014 | AUM-601 | AUM601 | AUM 601 |
| 相關(guān)產(chǎn)品 | L-Phenylalanine | Quinolinic acid | L-Glutamic acid | glycine | Memantine | L-Glutamic acid monosodium salt | N-Methylsarcosine | Memantine hydrochloride | Kynurenic acid | Indole-2-carboxylic acid | Decanoic Acid | N,N-Dimethylglycine hydrochloride |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 589.8595萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學試劑,生物技術(shù)服務 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務 |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
VIP1年
|
陜西締都醫(yī)藥有限責任公司
|
2026-04-22 | |
| 詢價 |
VIP5年
|
湖北魏氏化學試劑股份有限公司
|
2026-06-03 | |
| 詢價 |
VIP16年
|
上海諾太醫(yī)藥科技有限公司
|
2026-01-04 |